NovaBay Pharmaceuticals Price To Sales vs. Net Income
| NBY Stock | USD 0.60 0.01 1.69% |
NovaBay Pharmaceuticals Price To Sales Ratio |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.8 | 0.5361 |
|
|
For NovaBay Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NovaBay Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NovaBay Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NovaBay Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NovaBay Pharmaceuticals over time as well as its relative position and ranking within its peers.
NovaBay |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. If investors know NovaBay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NovaBay Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (74.61) | Revenue Per Share 9.028 | Quarterly Revenue Growth (0.25) | Return On Assets (0.39) | Return On Equity (2.64) |
The market value of NovaBay Pharmaceuticals is measured differently than its book value, which is the value of NovaBay that is recorded on the company's balance sheet. Investors also form their own opinion of NovaBay Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NovaBay Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NovaBay Pharmaceuticals' market value can be influenced by many factors that don't directly affect NovaBay Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NovaBay Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if NovaBay Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NovaBay Pharmaceuticals Net Income vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NovaBay Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare NovaBay Pharmaceuticals value to that of its competitors to determine the firm's financial worth. NovaBay Pharmaceuticals is rated below average in price to sales category among its peers. It is regarded third in net income category among its peers . At this time, NovaBay Pharmaceuticals' Price To Sales Ratio is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NovaBay Pharmaceuticals' earnings, one of the primary drivers of an investment's value.NovaBay Net Income vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
NovaBay Pharmaceuticals |
| = | 0.23 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
NovaBay Pharmaceuticals |
| = | (9.64 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
NovaBay Net Income Comparison
NovaBay Pharmaceuticals is currently under evaluation in net income category among its peers.
NovaBay Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NovaBay Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NovaBay Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of NovaBay Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of NovaBay Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -247.5 K | -259.9 K | |
| Operating Income | -5 M | -5.3 M | |
| Income Before Tax | -9.6 M | -10.1 M | |
| Total Other Income Expense Net | -4.6 M | -4.4 M | |
| Net Loss | -9.6 M | -10.1 M | |
| Income Tax Expense | 35.1 K | 36.9 K | |
| Net Loss | -14.6 M | -15.4 M | |
| Net Loss | -13.7 M | -14.4 M | |
| Non Operating Income Net Other | -4.1 M | -3.9 M | |
| Interest Income | 4.7 M | 2.9 M | |
| Change To Netincome | -3.1 M | -2.9 M | |
| Net Loss | (80.05) | (84.05) | |
| Income Quality | 0.43 | 0.51 | |
| Net Income Per E B T | 1.38 | 0.84 |
NovaBay Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NovaBay Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NovaBay Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NovaBay Pharmaceuticals' important profitability drivers and their relationship over time.
Use NovaBay Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NovaBay Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NovaBay Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.NovaBay Pharmaceuticals Pair Trading
NovaBay Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to NovaBay Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NovaBay Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NovaBay Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NovaBay Pharmaceuticals to buy it.
The correlation of NovaBay Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NovaBay Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NovaBay Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NovaBay Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NovaBay Pharmaceuticals position
In addition to having NovaBay Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run World Allocation Funds Thematic Idea Now
World Allocation Funds
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.